drugset / Trial / NCT06902740
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
Phase 4
Recruiting
300 enrolled
Peking Union Medical College Hospital
Baotou Central Hospital · collabCangzhou Hospital of Integrated Traditional Chinese and Western Medicine · collabChinese PLA General Hospital · collabChongqing General Hospital · collabFirst Affiliated Hospital of Harbin Medical University · collabHebei General Hospital · collabHuashan Hospital · collabJining First People's Hospital · collabLiaocheng People's Hospital · collabNanjing First Hospital, Nanjing Medical University · collabTaihe Hospital · collabTangshan Worker's Hospital · collabThe Affiliated Hospital of Qingdao University · collabThe First Affiliated Hospital of Zhengzhou University · collabWeifang People's Hospital · collabZhongnan Hospital · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial designed to evaluate the efficacy and safety of PCSK9 inhibitor combined with statin therapy compared to statin monotherapy in reversing asymptomatic intracranial atherosclerosis, assessed using high-resolution magnetic resonance imaging of the intracranial vessel walls.
Timeline
- Start
- 2025-11-07
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Publications
- Results Perez de Isla L, Diaz-Diaz JL, Romero MJ, Muniz-Grijalvo O, Mediavilla JD, Argueso R, Sanchez Munoz-Torrero JF, Rubio P, Alvarez-Banos P, Ponte P, Manas D, Suarez Gutierrez L, Cepeda JM, Casanas M, Fuentes F, Guijarro C, Angel Barba M, Saltijeral Cerezo A, Padro T, Mata P; SAFEHEART Study Group. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study. Circulation. 2023 May 9;147(19):1436-1443. doi: 10.1161/CIRCULATIONAHA.122.062557. Epub 2023 Apr 3.
- Results Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
- Results Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016 Dec 13;316(22):2373-2384. doi: 10.1001/jama.2016.16951.
- Results Kim BS, Lim JS, Jeong JU, Mun JH, Kim SH. Regression of asymptomatic intracranial arterial stenosis by aggressive medical management with a lipid-lowering agent. J Cerebrovasc Endovasc Neurosurg. 2019 Sep;21(3):144-151. doi: 10.7461/jcen.2019.21.3.144. Epub 2019 Sep 30.
- Results Miao H, Yang Y, Wang H, Huo L, Wang M, Zhou Y, Hua Y, Ren M, Ren C, Ji X, Yang Q, Guo X. Intensive Lipid-Lowering Therapy Ameliorates Asymptomatic Intracranial Atherosclerosis. Aging Dis. 2019 Apr 1;10(2):258-266. doi: 10.14336/AD.2018.0526. eCollection 2019 Apr.
- Results Zhu J, Wang Y, Li J, Deng J, Zhou H. Intracranial artery stenosis and progression from mild cognitive impairment to Alzheimer disease. Neurology. 2014 Mar 11;82(10):842-9. doi: 10.1212/WNL.0000000000000185. Epub 2014 Jan 31.
- Results Zhao D, Guallar E, Qiao Y, Knopman DS, Palatino M, Gottesman RF, Mosley TH Jr, Wasserman BA. Intracranial Atherosclerotic Disease and Incident Dementia: The ARIC Study (Atherosclerosis Risk in Communities). Circulation. 2024 Sep 10;150(11):838-847. doi: 10.1161/CIRCULATIONAHA.123.067003. Epub 2024 Aug 1.
- Results Gao P, Wang T, Wang D, Liebeskind DS, Shi H, Li T, Zhao Z, Cai Y, Wu W, He W, Yu J, Zheng B, Wang H, Wu Y, Dmytriw AA, Krings T, Derdeyn CP, Jiao L; CASSISS Trial Investigators. Effect of Stenting Plus Medical Therapy vs Medical Therapy Alone on Risk of Stroke and Death in Patients With Symptomatic Intracranial Stenosis: The CASSISS Randomized Clinical Trial. JAMA. 2022 Aug 9;328(6):534-542. doi: 10.1001/jama.2022.12000.
- Results Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011 Sep 15;365(11):993-1003. doi: 10.1056/NEJMoa1105335. Epub 2011 Sep 7.
- Results Li S, Tang M, Zhang D, Han F, Zhou L, Yao M, Li M, Cui L, Zhang S, Peng B, Jin Z, Zhu Y, Ni J. The prevalence and prognosis of asymptomatic intracranial atherosclerosis in a community-based population: Results based on high-resolution magnetic resonance imaging. Eur J Neurol. 2023 Dec;30(12):3761-3771. doi: 10.1111/ene.16057. Epub 2023 Sep 22.
- Results Gutierrez J, Khasiyev F, Liu M, DeRosa JT, Tom SE, Rundek T, Cheung K, Wright CB, Sacco RL, Elkind MSV. Determinants and Outcomes of Asymptomatic Intracranial Atherosclerotic Stenosis. J Am Coll Cardiol. 2021 Aug 10;78(6):562-571. doi: 10.1016/j.jacc.2021.05.041.
- Results Wong KS, Ng PW, Tang A, Liu R, Yeung V, Tomlinson B. Prevalence of asymptomatic intracranial atherosclerosis in high-risk patients. Neurology. 2007 Jun 5;68(23):2035-8. doi: 10.1212/01.wnl.0000264427.09191.89.
- Results Wong KS, Huang YN, Yang HB, Gao S, Li H, Liu JY, Liu Y, Tang A. A door-to-door survey of intracranial atherosclerosis in Liangbei County, China. Neurology. 2007 Jun 5;68(23):2031-4. doi: 10.1212/01.wnl.0000264426.63544.ee.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recaticimab | Monoclonal antibody | 450 mg | Subcutaneous |
| Comparator | Atorvastatin | Small molecule | 20 mg | — |
| Comparator | Rosuvastatin | Small molecule | 10 mg | — |